Annexon, Inc.
ANNX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001528115
In the last 90 days, Annexon, Inc. insiders filed 1 open-market purchase and 0 sales; 216 institutions reported holding it in 13F filings for Q2 2026, worth $1.02B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Annexon, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $99.8K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$99.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Annexon, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Love Douglas | PRESIDENT AND CEO | 390,476 | Sep 25, 2026 | 2 |
| Blumenkranz Mark S. | Director | – | Aug 12, 2026 | 1 |
| Satter Muneer A | Director | 10,342,134Indirect | Jun 15, 2026 | 4 |
| Jones William A Jr | Director | – | Jun 15, 2026 | 1 |
| Waddill William D. | Director | – | Jun 15, 2026 | 1 |
| Choi Jung | Director | 33,000Indirect | Jun 15, 2026 | 2 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 184,807 | Jun 15, 2026 | 4 |
| Carson William H. | Director | 78,405 | Jun 15, 2026 | 8 |
| Cockroft Bettina M. | Director | – | Jun 15, 2026 | 1 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 170,700 | Mar 4, 2026 | 3 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 123,582 | Mar 4, 2026 | 3 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 182,625 | Mar 4, 2026 | 3 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 | Mar 4, 2026 | 3 |
| Wiggans Thomas G | Director | – | Jun 9, 2025 | 0 |
| Bain Capital Life Sciences Fund, L.P. | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| BCIP Life Sciences Associates, LP | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Mattheakis Larry | EVP & Chief Scientific Officer | 17,188 | Jul 13, 2022 | 0 |
| Keswani Sanjay Chandru | EVP & Chief Medical Officer | 12,500 | Feb 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2025 (view filing) | Jul 14 | 2 days | Yednock TedEVP & CHIEF INNOVATION OFFICER | SSale | −1.12K | $2.58 | −$2.88K | −1.1%105.1K after | |
| Aug 1, 2025 (view filing) | Jul 30 | 2 days | Carson William H.Director | PPurchase | +4.12K | $2.43 | +$10.0K | +13.8%33.8K after | 10b5-1 |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Carson William H.Director | PPurchase | +4.12K | $2.09 | +$8.60K | +12.2%37.9K after | 10b5-1 |
| Oct 2, 2025 (view filing) | Sep 30 | 2 days | Carson William H.Director | PPurchase | +4.12K | $3.05 | +$12.6K | +10.8%42.1K after | 10b5-1 |
| Oct 31, 2025 (view filing) | Oct 30 | 1 day | Carson William H.Director | PPurchase | +4.12K | $3.17 | +$13.0K | +9.8%46.2K after | 10b5-1 |
| Nov 19, 2025 (view filing) | Nov 17-19 | 2 days | Satter Muneer ADirector | PPurchase | +1.50M | $3.37 | +$5.05M | +20.3%8.91M after | 3 lots |
| Nov 21, 2025 (view filing) | Nov 20-21 | 1 day | Satter Muneer ADirector | PPurchase | +822.6K | $4.38 | +$3.60M | +9.2%9.73M after | 2 lots |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Choi JungDirector | PPurchase | +33.0K | $4.19 | +$138.3K | New position33.0K after | |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Carson William H.Director | PPurchase | +4.12K | $4.47 | +$18.4K | +8.9%50.3K after | 10b5-1 |
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Carson William H.Director | PPurchase | +4.12K | $5.02 | +$20.7K | +8.2%54.4K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | SSale | −7.85K | $5.11 | −$40.1K | −6.5%113.8K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Dananberg JamieCHIEF MEDICAL OFFICER | SSale | −5.29K | $5.10 | −$27.0K | −6.7%73.2K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | SSale | −6.22K | $5.10 | −$31.7K | −4.8%124.5K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Yednock TedEVP & CHIEF INNOVATION OFFICER | SSale | −7.86K | $5.11 | −$40.1K | −7.5%97.2K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER | SSale | −5.29K | $5.10 | −$27.0K | −4.1%123.5K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | SSale | −5.57K | $5.42 | −$30.2K | −3.2%170.7K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Dananberg JamieCHIEF MEDICAL OFFICER | SSale | −5.82K | $5.43 | −$31.6K | −4.5%123.6K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | SSale | −4.34K | $5.42 | −$23.5K | −2.3%182.6K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Yednock TedEVP & CHIEF INNOVATION OFFICER | SSale | −5.57K | $5.42 | −$30.2K | −3.5%154.2K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER | SSale | −5.89K | $5.43 | −$32.0K | −3.2%180.1K after | |
| Mar 12, 2026 (view filing) | Mar 10 | 2 days | Carson William H.Director | PPurchase | +8.00K | $5.67 | +$45.4K | +14.7%62.4K after | 10b5-1 |
| Apr 14, 2026 (view filing) | Apr 10 | 4 days | Carson William H.Director | PPurchase | +8.00K | $6.20 | +$49.6K | +12.8%70.4K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11 | 2 days | Carson William H.Director | PPurchase | +8.00K | $5.78 | +$46.2K | +11.4%78.4K after | 10b5-1 |
| May 29, 2026 (view filing) | May 28 | 1 day | Satter Muneer ADirector | PPurchase | +613.5K | $5.41 | +$3.32M | +6.3%10.3M after | |
| Sep 25, 2026 (view filing)4:15 PM ET | Sep 24 | 1 day | Love DouglasPRESIDENT AND CEO | PPurchase | +26.1K | $3.83 | +$99.8K | +7.2%390.5K after |